Given the reduction in expression of phospho AKT and NF-kB, along with the reduced expression of VEGF-A in DU145 and 22Rv1 prostate cancer cells treated with VK2, we next sought to determine whether treatment with VK2 reduces angiogenesis in vivo. The gene discussed is VEGFA; the disease is prostate carcinoma.